Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

✅️ ELTP Catalyst ✅️

✅️ 1. Cash Flow Positive
✅️ 2. Purchase their original cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched
✅️ 4. Adderall XR $865 Million IMS market Approved and Launched
✅️ 5. Double digit quarterly revenues in millions
✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 8. Generic OxyContin - FIRST TO FILE ? FDA Aug 17, 2023 $720 Million
✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023
✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023
✅️ 11. Lease a second manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__12. Obtain Full ownership of generic Adderall IR $ 421.7 Million
__13. Obtain Full ownership of generic Adderall XR $ 865 Million
✅️ 14. Generic Methotrexate Antimetabolite- Approval
✅️ 15. Launch generic Methotrexate $63 Million
✅️ 16. $50+ million in yearly revenues
✅️ 17. Lowest PE ratio for OTC Healthcare sector
✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 22. Generic IR Adderall® Receives Marketing Approval from the Israeli Ministry of Health Oct 2024
✅️ 23. Final Approval of New Manufacturing Facility/Expansion
✅️ 24. Generate revenues over $20 million/quarter
✅️ 25. Generate revenues over $30 million/quarter
✅️ 26. Generate revenues over $40 million/quarter
__ 27. Generate revenues over $50 million/quarter
✅️ 28. Double output of manufacturing and packaging facilities
✅️ 29. Launch approved generic Tylenol with Codeine $47 Million
✅️ 30. Launch approved generic Norco - Hydrocodone acetaminophen IMS $300 Million
✅️ 31. Launch approved generic Percocet - Oxycodone acetaminophen IMS $317 Million
__ 32. Launch approved generic Dolophine - Methadone HCL tablets IMS $30 Million
✅️ 33. Dopamine Agonist Approval Requip XL $12 Million
✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion
✅️ 35. Agreement with Indian Research and Development Co.(R&D)
__ 36. Positive BE Study for generic Concerta CNS Stimulant $1.16 Billion
✅️ 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024
__38. Generic Concerta- FDA submission $1.16 Billion
✅️ 39. Launch Adderall IR in Israel
✅️ 40. Second order of Adderall IR by Israel
✅️ 41. $150+ million revenues a year run rate
__42. Generic OxyContin FDA Approval $720 Million
✅️ 43. Accord Pharma prevail over Purdue in Generic OxyContin infringement suit
https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf

https://www.reuters.com/legal/government/us-supreme-court-will-not-hear-purdue-appeal-oxycontin-patent-case-2025-10-06/#:~:text=The%20court%20decided%20not%20to,drug%20designed%20to%20US Oct 06, 2025
__44. Elite prevail over Purdue in Generic OxyContin infringement suit.
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__45. Launch generic OxyContin $720 Million
__46. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone this was Drug C in SequestOx reformulation trial
__47. Partner for SequestOx Abuse Deterrent Oxycodone
__48. $200 million in yearly revenue
__49. Undisclosed Mikah ANDA(s)
✅️ 50. DEA increases manufacturing quotas for Adderall & Vyvance for a second time - Oct 2025
✅️ ✅️✅️ 51. Positive Pivotal BE Undisclosed ANDA JUNE 2025 🔥 $27 Billion Market 🔥 generic anticoagulant
✅️ 52. DEA increases manufacturing quotas for Adderall & Vyvance AGAIN - Jan 2026
__53. Purchase a needle mover ANDA $Billion + market
__54. Complete stability testing for $27 Billion anticoagulant
__55. FDA Submission $27 Billion generic anticoagulant
__56. Generic Concerta Launch $1.16 Billion
__57. DollarLand SP
__58. Uplist to NASDAQ exchange
✅️ 59. Receive additional Analyst coverage from Zack’s Investment
✅️✅️✅️ 60. Select M&A advisory firm for buyout
✅️ 61. Perform Business Valuation
✅️ 62. First Walk Thru
__63. Buyout offer/s
__64. Buyer Identified
__65. Buyout Vote of Board of Directors
__66. Halt Trading
__67. Shareholder vote on offer
__68. Buyout Closing Completed —$$$$$$$$$$$
__69. 🔥Vegas BABY !!!!! 🔥
Bullish